Targeting BRAFV600E with specific BRAF inhibitors (BRAFi) in monotherapy (8, 9) and in combination with downstream MEK inhibitors (MEKi) (10–12) led to improved patient outcomes in different cancer entities, including gliomas (13–17). Here, BRAF is linked to central nervous system cancer.